Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Cytokinetics Incorporated, 3 years.
Cytokinetics Incorporated
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cytokinetics Incorporated May 15, 202487.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Cytokinetics Incorporated | Grant or award | +151 | $82.62 | $12,476 |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| Apr 15, 2026 | Cytokinetics Incorporated | Grant or award | +191 | $65.37 | $12,486 |
| Jan 15, 2026 | Cytokinetics Incorporated | Grant or award | +197 | $63.44 | $12,498 |
| Dec 1, 2025 | Cytokinetics Incorporated | Open-market sale | −2,150 | $66.80 | $143,620 |
| Oct 15, 2025 | Cytokinetics Incorporated | Grant or award | +199 | $62.80 | $12,497 |
| Sep 2, 2025 | Cytokinetics Incorporated | Open-market sale | −2,150 | $48.67 | $104,641 |
| Jul 15, 2025 | Cytokinetics Incorporated | Grant or award | +328 | $38.01 | $12,467 |
| May 14, 2025 | Cytokinetics Incorporated | Grant or award | +7,333 | — | — |
| Apr 15, 2025 | Cytokinetics Incorporated | Grant or award | +324 | $38.56 | $12,493 |
| Apr 3, 2025 | Cytokinetics Incorporated | Open-market sale | −450 | $39.43 | $17,744 |
| Mar 4, 2025 | Cytokinetics Incorporated | Open-market sale | −900 | $42.50 | $38,250 |
| Jan 2, 2025 | Cytokinetics Incorporated | Grant or award | +255 | $48.93 | $12,477 |
| Oct 1, 2024 | Cytokinetics Incorporated | Grant or award | +237 | $52.60 | $12,466 |
| Jul 5, 2024 | Cytokinetics Incorporated | Open-market sale | −253 | $54.61 | $13,816 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.